(PFSA)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
Profusa, Inc. develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
| Name | Position |
|---|---|
| Dr. Ben Chung-Bin Hwang Ph.D. | CEO & Chairman |
| Mr. David Icke | Head of Digital Health Business |
| Mr. Fred S. Knechtel | Chief Financial Officer |
| Mr. Phil Constantinou | Head of Software & Data Science |
| Mr. Sean Givens | Head of Government Business |
| Mr. William McMillan | Co-founder, Chief Scientific Officer & Head of Research |
| Date | Type | Document |
|---|---|---|
| 2026-03-13 | 8-K | ea0281550-8k_profusa.htm |
| 2026-02-02 | 8-K | ea0274366-8k_profusa.htm |
| 2026-01-02 | DEF 14A | ea0271275-01.htm |
| 2025-12-30 | 8-K | ea0271254-8k_profusa.htm |
| 2025-12-22 | PRE 14A | ea0270245-pre14a_profusa.htm |
| 2025-11-20 | 8-K | ea0265666-8k_profusa.htm |
| 2025-11-19 | 10-Q | ea0264995-10q_profusa.htm |
| 2025-11-14 | NT 10-Q | ea0265872-nt10q_profusa.htm |
| 2025-11-03 | 8-K | ea0263514-8k_profusa.htm |
| 2025-10-30 | 8-K | ea0263091-8k_profusa.htm |